# Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity

> **NCT03287960** · PHASE3 · COMPLETED · sponsor: **Rhythm Pharmaceuticals, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Leptin Receptor Deficiency Obesity

## Interventions

- **DRUG:** Setmelanotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03287960
- **Lead sponsor:** Rhythm Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-30
- **Primary completion:** 2020-09-25
- **Final completion:** 2020-09-25
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03287960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03287960, "Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03287960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*